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ABSTRACT
Purpose: Hyperthermia treatment quality determines treatment effectiveness as shown by the clinic-
ally derived thermal-dose effect relations. SAR based optimization factors are used as possible surro-
gate for temperature, since they are not affected by thermal tissue properties uncertainty and
variations. Previously, target coverage (TC) at the 25% and 50% iso-SAR level was shown predictive for
treatment outcome in superficial hyperthermia and the target-to-hot-spot-quotient (THQ) was shown
to highly correlate with predictive temperature in deep pelvic hyperthermia. Here, we investigate the
correlation with temperature for THQ and TC using an ‘intermediate’ scenario: semi-deep hyperthermia
in the head & neck region using the HYPERcollar3D.
Methods: Fifteen patient-specific models and two different planning approaches were used, including
random perturbations to circumvent optimization bias. The predicted SAR indicators were compared
to predicted target temperature distribution indicators T50 and T90, i.e., the median and 90th percent-
ile temperature respectively.
Results: The intra-patient analysis identified THQ, TC25 and TC50 as good temperature surrogates:
with a mean correlation coefficient R2T50¼ 0.72 and R2T90¼0.66. The inter-patient analysis identified the
highest correlation with TC25 (R2T50¼ 0.76, R2T90¼0.54) and TC50 (R2T50¼ 0.74, R2T90¼ 0.56).
Conclusion: Our investigation confirmed the validity of our current strategy for deep hyperthermia in
the head & neck based on a combination of THQ and TC25. TC50 was identified as the best surrogate
since it enables optimization and patient inclusion decision making using one single parameter.
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1. Introduction
The therapeutic benefit of hyperthermia as adjuvant to radio-
and chemo-therapy has been proved in a number of clinical
trials [1–3]. In the literature, treatment outcome has been
prospectively and retrospectively correlated to different ther-
mal dose parameters [4–6]. Following these thermal- and
thermal-dose effect relations, a target conformal increase of
the temperature should further enhance this clinical effect-
iveness [7]. However, temperature is difficult to predict, due
to large thermal tissue property uncertainties and hence can-
not be prescribed. Establishing a prescriptive quality param-
eter prognostic for the treatment outcome would help in the
development of new devices or techniques and for a further
spread of hyperthermia adoption as an addition to first line
radio- and chemo-therapy [8,9]. Although a single unique
thermal dose parameter has not been established, the need
for such a parameter is widely accepted by the hyperthermia
community [10–14].
Despite the demonstrated thermal- and thermal-dose-
effect relations, there is no consensus amongst hyperthermia
researchers whether the specific absorption rate (SAR) or
temperature distribution should be optimized [15]. Of course,
as increasing temperature is the main aim of hyperthermia,
optimizing the temperature distribution seems the most
logic objective and some effectiveness was shown [16].
However, for deep pelvic hyperthermia, the benefit of opti-
mizing the temperature pattern was lost under the very large
uncertainties of thermal tissue properties [13,17]. On top of
that, temperature optimization generally exploits global opti-
mizers, which are prone to suboptimal solutions and require
a considerable computational effort. Besides, global algo-
rithms require problem-specific parameter tuning and are
limited in handling large problem sizes, i.e., optimization
complexity rises exponentially with the number of unknowns
[18]. Optimization of the SAR pattern, on the other hand,
facilitates convex optimizers, which enable real-time re-
optimization during treatment [9]. The possibility of ascribing
treatment quality with SAR indicators is very attractive when
considering the above and taking also into account that
hyperthermia applicators are generally designed based on
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electromagnetic and dosimetric characteristics, which are
predictable at a higher accuracy [19,20].
In their study, Canters et al. [13] used the predicted tem-
perature parameters as a basis for selecting a set of quality
indicators and optimization functions for deep pelvic hyper-
thermia applied with the BSD2000 Sigma 60 applicator. Their
results distinguished the so-called target to hot-spot quotient
(THQ) as most predictive for median target temperature, T50.
Earlier, a relation was found between the Target Coverage of
the 25% iso-SAR volume and clinical outcome for superficial
hyperthermia [14]. Still, their predictive value for either clin-
ical outcome and temperature for other scenarios, such as
head & neck (H&N) hyperthermia, is unknown. In the work of
Iero et al. [21], in a simplified setup, the spatial relation
between the SAR and temperature is shown to mimic a con-
volution, with the Green’s function depending on the ther-
mal parameters. Hence, although a correlation between SAR
and temperature is to be expected, the actual predictive
power of SAR-based quality parameters should be verified in
a realistic clinical scenario like H&N hyperthermia.
At Eramsus MC, the Visualization Tool for Electromagnetic
Dosimetry and Optimization (VEDO) is used in clinical routine
to plan and visualize the administered hyperthermia treat-
ment. A key role is played by the possibility of performing
online treatment re-optimization in case of patient complain
(or in case of a negative feedback from the interstitial therm-
ometry, when available). Generally, this task as well as power
regulation, is based on the SAR statistics reported on the
VEDO console. These are aimed at objectively inform physi-
cians about the quality of the estimated administered treat-
ment [13]. In addition, we recently derived a dedicated set of
thermal tissue parameters enabling the prediction of median
target temperature T50 at an estimated accuracy better than
1 C [22]. Therefore, as clinical decision making is based on
SAR indicators, this paper aims to investigate the correlation
between these SAR quality indicators and the main predicted
temperature indicators.
The objective of this study was to evaluate the predictive
value of clinically adopted and relevant SAR based indicators
for treatment quality during H&N hyperthermia. Specifically,
two different evaluations have been carried out: (1) an intra-
patient analysis aimed at establishing the optimal SAR-based
parameter for optimization purposes on a per-patient basis;
(2) an inter-patient analysis aimed at determining which SAR-
based parameter is the most suitable for treatment decision
making and patient inclusion. The analysis has been con-
ducted using fifteen 3D models generated during hyperther-
mia treatment planning (HTP) for patients with H&N cancer
treated with HYPERcollar3D [23]. To avoid optimization bias,
two different optimization approaches and random perturba-
tions were adopted.
2. Materials & methods
2.1. Evaluation dataset
The evaluation dataset consists of fifteen 3D patient models
generated during HTP for patients with H&N cancer that
were planned for treatment with the HYPERcollar3D [23]. Six
of the fifteen included patient models showed a hyperther-
mia target volume1 (HTV) above 50cm3. These have been
marked as HTV> 50 cm3 (Table 2). Such a threshold was the-
oretically derived as the focusing capabilities of phased array
applicator [24–26] and experimentally shown in [23,27]. For
the case at hand, this has been evaluated to be approxi-
mately 50 cm3.
The HYPERcollar3D is a ring-shaped phased array made
up of twenty patch antennas distributed over three rings
and operating at 434MHz. Twelve out of the twenty anten-
nas are selected, as twelve amplifiers are available for the
clinical treatment [23]. A water bolus fills the space between
the applicator and the patient to avoid undesired heating
that may arise at the patient’s skin and to enhance electro-
magnetic coupling [23].
Patient specific 3D models and simulation results were
obtained using the clinical HTP procedure, as explained in
detail in Rijnen et al. [28] and Paulides et al. [15]. Below, the
HTP process is summarized following the scheme of Figure 1.
Patient-specific models were created by delineation of various
tissues based on computerized tomography scans using a cus-
tom atlas-based auto segmentation routine followed by a
manual adjustment in software tool iSeg (v.3.8 Zurich
Medtech, Zurich, Switzerland) [29]. Electromagnetic and con-
stant thermal tissues parameters, as reported in Table 1
Table 1. Electromagnetic and thermal tissue parameters at 434MHz accordingly to Verhaart et al. [22].
er r Sm
 
q kgm3
h i
c Jkg
 C
h i
k Wm1
 C
h i
Q Wkg
h i
x ½ml=minkg
Internal Air 1.0 0.0 1.2 – – – –
Lung 23.6 0.38 284 – – – –
Muscle 56.9 0.81 1090 3421 0.4 0.96 442.8
Fat 11.6 0.08 911 2348 0.5 0.51 255
Bone 13.1 0.09 1908 1313 0.32 15 10
Cerebrum 56.8 0.75 1045 3696 0.55 15.5 763.3
Cerebellum 55.1 1.05 1045 3653 0.51 15.7 770
Brain Stem 41.7 0.45 1046 3630 0.51 11.4 5586
Myelum 35 0.46 1075 3630 0.51 2.48 160.3
Sclera 57.4 1.01 1032 4200 0.58 5.89 380
Lens 37.3 0.38 1076 3133 0.43 – –
Vitreous Humor 69 1.53 1005 4047 0.59 – –
Optical Nerve 35 0.46 1075 3613 0.49 2.48 160.3
Cartilage 45.1 0.6 1100 3568 0.49 0.54 35
Thyroid 61.3 0.89 1050 3609 0.52 87.1 5624.3
HTV 59 0.89 1050 3950 1.5 – 848
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[22,28,29], were assigned to the segmented tissues of the 3-D
patient-specific models. Of this list, the greatest unknowns are
the thermal tissue properties. In previous work, we solved this
issue by determining tissue parameters specifically for this
application by parameter tuning such that the difference
between predicted values from HTP and invasively measured
temperatures in H&N tumors was minimized. Hence, while
every patient-model is different in morphology, these tissue
parameters aggregate information from a representative
group of H&N patients and, therefore, are appropriate for our
analysis [29]. The 3D patient-specific models were imported
into Sim4Life (v. 3.4 Zurich MedTech AG, Zurich, Switzerland)
along with a 3D applicator model including a water bolus
(modeled as water with r ¼ 0; 04 S=m [22,28–30]) between
the applicator and the patient surface. Using this setup, the
total field was computed for a 1-V sinusoidal signal excitation
at 434MHz for each antenna. The electric field per antenna
was normalized for 1W radiated power and the SAR pattern
optimized. The two optimization approaches used were the
particle swarm optimization (PSO) of the target to hot-spot
quotient (THQ) [28] and the FOcusing via Constrained power
Optimization (FOCO) [21]. These methods are described in the
following paragraphs. VEDO was used for optimization, visual-
ization and generating the SAR quality parameters [28].
2.1.1. PSO-Optimized target to hot-spot quotient
The optimization strategy implemented in VEDO is based on
the notion that planning in hyperthermia treatment is a
multi-objective optimization problem with a twofold aim: (1)
maximizing the SAR within the target volume and (2) mini-
mizing the SAR in hot-spots in healthy tissues. Starting from
this consideration, the cost function is the Target to Hotspot
SAR Quotient, defined as:
THQ ¼ <SARtarget>
<SARHS>
; (1)
where, <SARtarget> is the mean SAR in the target volume
and <SARHS> is the average SAR in hotspots, defined as the
1% volume of healthy tissues where the highest SAR occurs.
One percent was chosen since this is approximately 50ml,
i.e. 55 ± 8ml, and connects in absolute volume to the defin-
ition in Canters et al. where 0.1% was used for the pelvic
region. Note that the CT scan instruction for hyperthermia
are from tip of head to including supraclavicular [28]. Note
Figure 1. Schematic work-flow of the adopted methodology.
Table 2. Correlation coefficient (R2) with the median temperature T50 on a
per-patient basis.
ID TV [cm3] R2TC25 R
2
TC50 R
2
TC75 R
2
THQ
A 129.1 0.60 0.60 0.48 0.61
B 412.4 0.28 0.35 0.32 0.40
C 291.8 0.25 0.26 0.27 0.33
D 105.0 0.76 0.82 0.64 0.94
E 57.4 0.81 0.71 0.61 0.83
F 34.4 0.90 0.86 0.61 0.95
G 36.7 0.75 0.78 0.69 0.77
H 135.7 0.77 0.56 0.27 0.42
I 18.3 0.76 0.86 0.84 0.94
L 38.1 0.91 0.78 0.43 0.91
M 28.7 0.87 0.88 0.75 0.96
N 45.8 0.82 0.90 0.74 0.94
O 39.1 0.46 0.86 0.78 0.02
P 24.1 0.84 0.78 0.52 0.93
Q 242.6 0.93 0.85 0.61 0.87
mean 0.71 0.72 0.57 0.72
meanHTV<50cm3 0.79 0.84 0.67 0.80
meanHTV>50cm3 0.63 0.59 0.46 0.63
Note: Indicates if HTV > 50 cm3.
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that THQ is a-dimensional since it is the ratio of the average
SAR in two different volumes.
This optimization problem is non-convex and must be
tackled by a global optimizer, for which the Particle Swarm
Optimization (PSO) was used [31].
2.1.2. Focusing via constrained power optimization
An alternative strategy is to cast the HTP in terms of a con-
vex optimization problem that is aimed at restricting the SAR
level in the healthy tissues while maximizing SAR within the
hyperthermia target volume (HTV). In FOCO, hot-spot occur-
rence is prevented by a patient-specific mask function which
limits excessive power deposition level in healthy tissues.
When one of the field components can be considered to
be dominant above the other ones, by simply setting the
phase reference of the system, FOCO transforms the non-
convex problem into a convex one [32]. This results in only
one solution, i.e. the globally optimal one. A brief mathemat-
ical formulation of the adopted approach is given in
the following.
Let us consider r 2 X a generic point of the 3D region of
interest (X), the SAR can be expressed as: SAR(r)¼ r(r)jE(r)j2/
2q(r), where r is the conductivity [S/m], q is the mass density
[kg/m3] and jE(r)j2 is the squared amplitude of the total elec-
tric field generated by ‘weighted’ N monochromatic sources
surrounding X.
Considering a target point set within the target area
(rt2X) the constrained focusing problem can be stated as:
Determine the set of the array’s complex excitations coefficients
such to maximize the squared amplitude of the field in the target
point, i.e., jE(rt)j2, while enforcing arbitrary upper bounds in the rest
of the domain of interest.
This maximization problem is non-linear and belongs to
the class of NP-hard problems2 [18], as the cost functional
jE(rt)j2 is a non-negative quadratic polynomial with respect
to the unknowns, In. Hence, the global optimality of the solu-
tion is not ensured and global optimization procedures
are needed.
When one of the field components can be considered to
be dominant above the other ones, Ei rt . ., as in the case of
the HYPERcollar3D [33], FOCO circumvents the above diffi-
culty by exploiting the degree of freedom on the field phase
reference, assuming that the field in the target point is real
[21,34]. Under such a circumstance, the problem can then be
stated as:
Find In (n¼ 1,… ,N) such to:
max Ei rtð Þ
 
(2.a)
subject to:
I Ei rtð Þ
  ¼ 0 (2.b)
E rð Þ2 MF rð Þ r 2 X P rtð Þ (2.c)
Constraints (2.b)–(2.c) define a convex set of unknowns
[34]. The cost function (2.a) is a linear function of the
unknowns. Hence, the overall constrained focusing problem
is now conveniently cast as a convex programing problem.
As such, the globally optimal solution can be efficiently
determined via local optimization procedures. Finally, the
‘mask’ function, i.e., MF (r) is a non-negative arbitrary func-
tion. It allows enforcing patient-specific constraints on the
power deposition outside the target area, i.e., P(rt), which is
defined accordingly to Bellizzi et al. [33].
The mask function is set as MF (r)¼A/(rN(r)þ A) where
rN(r) represents the electric conductivity distribution normal-
ized to the maximum values in each patient and A is a scalar
set according to Bellizzi et al. [32]. Hence, the maximum
allowed electrical field value in normal tissue is related to
SAR by using a mask function weighted to the tissue specific
conductivity. In addition, FOCO aims at maximizing the SAR
in the HTV while enforcing constraints elsewhere. Note that
this formulation always results in high THQ values independ-
ent of the actual mask.
2.2. Quality indicators
The SAR quality indicators studied are used in the clinic and
hence implemented in VEDO. These allow understanding of
the quality of the SAR distribution induced into the patient.
The considered quality indicators are the target coverage
and the THQ. The target coverage has been evaluated at
25%/50%/75% (TC25/TC50/TC75) level and is defined as the
volume percentage of the HTV covered by 25%/50%/75%
iso-SAR value when the SAR distribution is normalized to the
maximum SAR in the whole patient model. As an example,
TC25 equal to 50% means that the normalized SAR distribu-
tion is 0,25 in one half of the HTV. THQ is defined in
Section 2.1.1.
A straightforward way to analyze the quality of a hyper-
thermia treatment is to take into account both the power
deposited within the HTV and the SAR peaks outside, i.e.,
the so called hot-spots. As a matter of fact, the target
coverage gives information on the iso-SAR level covering
the HTV, i.e., within the target volume, whereas the THQ is
somehow a balance of the power deposited within and
outside the HTV (note, 1/THQ was also investigated in
[13]). Hence, we decided to investigate these SAR quality
metrics as particularly suitable and relevant for
this analysis.
SAR-based indicators have been correlated to tempera-
ture-based indicators being correlated to clinical outcome
[4–6,10–13]. Those are the T50 and the T90, defined as the
lower temperature covering respectively 50% or 90% of the
HTV volume.
Our analyses have been carried out evaluating the
correlation coefficient (R2) for each of the considered SAR
indicators with both T50 and T90. The values of the coeffi-
cients R2 2 (0,1) indicate the degree of correlation between
the SAR quality indicators and the predicted T50 or T90. In
all temperature calculations, the input power was increased
up to maximum patient tolerance, i.e., until the temperature
in normal tissue reaches 44 C. Considering two variable,
A and B, with N scalar observations, then the correlation
INTERNATIONAL JOURNAL OF HYPERTHERMIA 459
coefficient is defined as:
q A; Bð Þ ¼ 1
N 1
XN
i¼1
AilA
rA
 
BilB
rB
 
(3)
where, lA/B and rA/B are the mean and standard deviation of
A and B, respectively. In this analysis, A represents the SAR
quality metrics (i.e., TC25, TC50, TC75 and THQ) and B the
chosen temperature outcome metrics (i.e., T50 and T90). The
calculated correlation coefficients have been analyzed by
two different evaluations. A first per-patient analysis, i.e.,
intra-patient, aimed at investigating and identifying the best
SAR-based cost function for optimization purposes. A second
inter-patient analysis was then aimed at determining the
most temperature predictive parameter to be used for deci-
sion making and patient inclusion.
It is worth to note that FOCO was needed in addition to
the THQ PSO-optimized approach for our purpose in the pre-
sented analysis. First, because we recently showed that the
FOCO approach performs better in terms of T50 predictions
for large target volumes [32]. Second, the above described
THQ PSO-optimized approach would have been intrinsically
biased since the cost function, i.e., THQ, is also one of the
evaluation metrics. Therefore, we deem our current approach
of using two different optimization algorithms with different
levels of perturbations more suitable for this analysis.
2.3. Details on data generation
The goal of this work was to assess if SAR-based quality met-
rics are correlated with treatment quality, using the predicted
median temperature, T50, and the T90 as surrogate of the
clinical outcome (i.e., accounting for the treatment outcome).
The overall process is summarized in a flowchart depicted in
Figure 1.
Our procedure starts with optimizing the complex signals
feeding the applicator by means of the two optimization
routines. For each patient, both HTP optimizers lead to a cor-
responding optimized excitation set (In
opt) (middle dashed
box in Figure 1). These latter are determined such that the
induced SAR distribution is focused within the target volume.
This corresponds to ‘high’ values of the SAR quality parame-
ters. By considering only this subset of the data, our evalu-
ation would contain an optimization bias. Hence, for each
patient, we extended the dataset by generating various exci-
tation signals inducing several distinct SAR distributions. For
each, we calculated the induced temperature distributions.
Hereto, we perturbed the optimized excitation signals, i.e.,
In
opt. Obviously, the more we perturb the optimal excitation
signals, the more the SAR distribution parameters deviate
from the optimal values. In this way, also the lower values of
the SAR quality metrics are achieved. This approach was
used and deemed better than choosing completely random
excitations, as in that case, focusing would not occur at all.
By doing so, one is able to evaluate the possible correlations
based on relevant results (orange bottom dashed box in
Figure 1).
As far as the realization of the perturbations is concerned,
20 different cases were considered for each patient and each
optimized complex signal. Hereto, both the amplitude (jIoptn j)
and phase (/Ioptn ) of the excitations were perturbed as jInj ¼
ð1þ bunÞjIoptn j and /In ¼ ð1þ bvnÞ/Ioptn ; where un and vn are
random uniformly distributed numbers 2 ½1; 1 and b moni-
tors the perturbation intensity (from 65% to 6100% in steps
of 5%). In conclusion, SAR distributions for 2 optimization
routines, 15 patient models and 21 complex signals were
used for evaluating the correlations. Of course, in each
experiment (and for each optimizer and each antenna) the
perturbation was randomly determined according to the
enforced distribution. Note that our goal was not to simulate
noise but rather perturbations. Hence, similar results are
expected if perturbations are applied in some other way.
2.4. Details on the bio-heat transfer calculation
The initial body temperature is set according to the physio-
logic body temperature, i.e., set equal to 37 C. The water
bolus boundary condition was modelled as a convective
boundary condition with a heat transfer coefficient of 292W/
m2kg C and a temperature of 30 C whereas the internal air
boundary condition was modelled using a heat transfer coef-
ficient of 50W/m2kg C and a temperature of 37 C [22].
Finally, the external air boundary condition was modelled
with a heat transfer coefficient of 850W/m2kg C and assum-
ing a room temperature of 20 C [22]. Temperature simula-
tions were calculated in Sim4Life software using Pennes’ Bio-
Heat equation [35]. Steady state temperatures were obtained
by increasing total radiated power of the antennas com-
bined, and hence SAR, to achieve a maximum of 44 C in
normal tissue, where normal tissue are all tissues outside
the HTV.
3. Results
Tables 2 and 3 report the results of the intra-patient analysis.
Here, the correlation coefficients between the considered
SAR indicator set with both T50 and T90 (respectively in
Tables 2 and 3) have been evaluated for each patient
Table 3. Correlation coefficient (R2) with the median temperature T90 on a
per-patient basis.
ID TV [cm3] R2TC25 R
2
TC50 R
2
TC75 R
2
THQ
A 129.1 0.52 0.55 0.47 0.65
B 412.4 0.34 0.37 0.36 0.20
C 291.8 0.05 0.07 0.12 0.28
D 105.0 0.80 0.81 0.60 0.92
E 57.4 0.73 0.49 0.40 0.74
F 34.4 0.70 0.47 0.25 0.56
G 36.7 0.69 0.53 0.40 0.77
H 135.7 0.63 0.61 0.45 0.28
I 18.3 0.74 0.85 0.81 0.91
L 38.1 0.86 0.88 0.59 0.94
M 28.7 0.82 0.87 0.75 0.93
N 45.8 0.83 0.82 0.53 0.91
O 39.1 0.50 0.83 0.62 0.02
P 24.1 0.82 0.73 0.52 0.91
Q 242.6 0.91 0.80 0.57 0.87
mean 0.66 0.65 0.50 0.66
meanHTV<50cm3 0.75 0.75 0.56 0.74
meanHTV>50cm3 0.57 0.53 0.42 0.56
Note: Indicates if HTV > 50 cm3.
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separately. A mean correlation coefficient R2¼ 0.72 for T50
and of R2¼0,66 for T90 were found. This suggests that TC25
and TC50 can be exploited for optimization purposes besides
THQ. Instead, a weaker correlation was found for TC75 with
both T50 and T90, i.e. R2¼ 0.57 and R2< 0.5 respectively. The
same trend is observed for the smaller and the larger HTV
volume classes.
Figures 2 and 3 report the results of the inter-patient ana-
lysis. Each sub-graph reports the comparison of one of the
considered SAR-based quality metrics set with T50 and T90,
in Figures 2 and 3 respectively. Following the procedure in
Section 2.3, each star represents the value of a SAR-based
quality metric (i.e., THQ and TC25/50/75) and the corre-
sponding temperature metric (i.e., T50 and T90). Here, the
correlation coefficients between SAR quality indicator and
the temperature metrics have been evaluated considering all
included patients combined. A sub-graph for each indicator
is reported and the correlation to the target temperature
metrics have been calculated and reported. Results achieved
in our inter-patient analysis identified a good correlation of
temperature metrics with TC25 (R2T50¼ 0.76, R2T90¼0.56) and
TC50 (R2T50¼ 0.74, R2T90¼ 0.56), and a weaker one with TC75,
THQ where R2 remains< 0.5.
Table 4 reports the results shown in Figures 2 and 3 for
the smaller and larger target volumes separately, using
HTV¼ 50 cm3 as threshold. Figures 2 and 3 show the results
for smaller target volumes in green whereas the larger in
blue. Table 4 confirms the relations with TC25, TC50 and
TC75, whereas the THQ-related correlation coefficients are
different for different sized target volumes. In particular,
these are greater in case of HTV< 50 cm3 (R2T50¼ 0.46,
R2T90¼ 0.15) and decrease in case of larger HTV
(R2T50¼ 0.37, R2T90¼ 0.01).
4. Discussion
In this work we investigated the correlation of SAR quality
indicators with treatment quality outcome for the head and
neck region using the HYPERCollar3D applicator. Our intra-
patient analysis confirmed the clinically adopted THQ as a
good SAR optimization function and identified TC25 and
TC50 as possible optimization functions. On the other side,
in contrast with what found by Canters et al. [13] for deep
pelvic hyperthermia, the inter-patient analysis herein
reported identified a better correlation of TC25 and TC50, as
compared to THQ, to the predicted temperature. As such, for
the case of head and neck with the HYPERCollar3D applica-
tor, both TC25 and TC50 are a better discriminant for the
quality of a treatment.
Treatment quality has been herein evaluated according to
the thermal dose effect relations which advocate the use of
CEM43CT90 [2] and the median HTV temperature T50 [7].
For the particular case of head and neck hyperthermia,
Verhaart et al. [22] showed that T50 can be predicted with a
median accuracy of 0.8 C, even when ignoring the
Figure 2. Inter-patient correlation of all indicators with T50. Each indicator is individually plotted. On each subfigure, the SAR indicator name is displayed and the
correlation coefficients (R2) are reported.
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temperature dependence of tissue cooling. Although thermal
modeling is generally strongly affected by uncertainties, the
thermal tissue properties used in this study were optimized
and validated using temperatures measured by interstitially
placed thermometer probes [21,23]. Hence, our 3D simula-
tions provide the level of certainty required for predictive
simulations for this specific application. Also, Kok at al. [36]
indicated that, although absolute temperature simulations
are affected by uncertainties, relative changes can be pre-
dicted with good accuracy. However, an important ‘parallel’
effect of hyperthermia is perfusion increase [37] and this was
shown to play a crucial role in exploiting 3D dosimetry based
on patient-specific temperature simulations [22]. Here, group
optimized constant thermal tissue properties were used in all
patients. Hence, based on the clinical dose effect relation, we
adopted temperature-based quality parameters, i.e., T50 and
T90, as surrogates for treatment clinical outcome. Finally, the
chosen SAR indicator set was deducted from the one
embedded into the VEDO console as clinic decision making
is currently based on these indicators. Also, similar SAR indi-
cators set were already investigated in [13] and [14] and cor-
related to treatment quality respectively for deep
hyperthermia in the pelvic region and for superficial
hyperthermia.
4.1. Intra-patient analysis
In the current clinical optimization routine at the Erasmus
MC, the planning of a hyperthermia treatment for the head
and neck region is performed by optimizing the THQ [9,28].
The results delivered by our intra-patient analysis confirmed
the effectiveness of this approach, as THQ was found to
highly correlate to the target temperatures indicators, as
shown in Tables 2 and 3. However, our results also suggest
TC50 and TC25 as suitable optimization functions. Due to
the high focusing capabilities of the HYPERCollar3D, it is
worth noting that the HYPERCollar3D is able to deliver a
conformal heating pattern so TC25 values are always high
(75%). Therefore, TC50 is a more sensitive cost function
that will allow improving T50 also towards 43 C.
The results for Patient O were specifically analyzed
because of the very low correlation between THQ and ther-
mal proprieties found, as in Tables 2 and 3. Here, a large
metal implant that strongly disturbed the SAR distribution
was present in the target area leading to a very high local
Figure 3. Inter-patient correlation of all indicators with T90. Each indicator is individually plotted. On each subfigure, the SAR indicator name is displayed and the
correlation coefficients (R2) are reported.
Table 4. Inter-patient correlation coefficient (R2) with T50 and T90 for all
patients and separately for the large and small cases.
T50 T90
Overall HTV< 50cm3 HTV> 50cm3 Overall HTV< 50cm3 HTV> 50cm3
R2TC25 0.76 0.76 0.73 0.54 0.47 0.56
R2TC50 0.74 0.74 0.68 0.56 0.54 0.48
R2TC75 0.49 0.48 0.51 0.38 0.36 0.35
R2THQ 0.37 0.46 0.37 0.11 0.15 0.01
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temperature peak. To show that the effect of this peculiar
(clinically realistic) case does not affect the overall analysis,
we also evaluated all statistics excluding this case. The
results remain consistent, i.e., a maximum difference of 3% in
TC25/50/75 and  14% in THQ, where R2 still always remains
below 0.45.
4.2. Inter-patient analysis
The presented analysis shows a different SAR-temperature
relation for the head and neck region as compared to the
one for deep regional hyperthermia [13], where THQ was
found to be most favorable quality indicator. Our results,
instead, show that THQ correlates poorly to the predicted
target temperature (R2< 0.5) whereas TC25 and TC50 correl-
ate better to the predicted temperature. Note that the heat-
ing patterns achieved during H&N hyperthermia with
HYPERCollar3D applicator and deep pelvic hyperthermia are
very different. A much more target conformal heating is
achieved, and undesired SAR secondary peaks generally
occur in proximity of the skin, as shown in Figure 4. Overall,
the coverage factor accounts for the amount of power
deposited within the target area while the limiting hot-spot
effect is reduced by the water bolus, e.g., in Figure 4. Hence,
the predictive value of THQ is lower in semi-deep hyperther-
mia compared to deep-regional hyperthermia in the pelvis.
We found that TC25 and TC50 are the most favorable SAR
indicators. This matches with the study by Lee et al. [14],
whom identified a correlation between treatments in which
TC25 was above 75% as indicator for a good treatment.
Using our results, this would mean that on average T50
should be greater than 40 C.
Finally, we conducted the same analysis for the data with-
out patient O. The mean values derived in our intra-patient
analysis (Tables 2 and 3) differ maximum for  5% when
excluding this difficult, but realistic, case.
Figure 4. Normalized SAR distribution (left column) and corresponding temperature distribution (right column) for patients ID E, D and F (1st, 2nd and 3rd row
respectively). Undesired heating in the proximity of the skin is mitigated by the effect of the water bolus.
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5. Conclusion
In this work, we evaluated the predictive value of clinically
adopted and relevant SAR indicators in H&N hyperthermia
for treatment quality. The analysis has been conducted using
fifteen 3D patient specific models generated during HTP for
patients with H&N cancer treated with HYPERcollar3D. In
order to avoid optimization bias, two different optimization
approaches have been used and 21 different random pertur-
bations levels for each optimization approach and each
patient were considered.
The inter-patient investigation identified a higher correl-
ation for TC50 (R2T50¼0.74, R2T90¼0.56) than for THQ
(R2< 0.5). Hence, the decision on whether to treat or not is
best based on TC50. The per-patient analysis identified equal
correlations between T50 and T90 with TC50 and THQ
(R2T50¼0.72, R2T90¼0.66). Hence, optimization of a per-patient
based during treatment can be done on both. These results
confirm the effectiveness of our current clinical approach.
However, in our quest towards standardized parameters and
since TC50 is already often used in applicator quality assur-
ance, we advocate using TC50 as optimization cost function
for target conformal applicators.
Results have been generated with specific reference to
patients with H&N cancer treated with HYPERcollar3D, i.e.
target conformal hyperthermia. Comparative evaluation of
our findings with the results from Canters et al. [13] for deep
pelvic HT with BSD systems revealed contrasting correlations
with temperature of the same SAR quality parameters.
Hence, we expect that the optimum optimization and evalu-
ation metric is dependent on the focusing ability of an appli-
cator. Such dependence would make our analysis very
important for new conformal applicators that are under
development [38–41]. Application of these results to other
anatomical sites and applicators are matter of
ongoing research.
Notes
1. HTV represents the target for the hyperthermia treatment and it is
delineated by a physician. Details in [31].
2. Non-determistic polynomial-time hard problem
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